{"pmid":32339362,"title":"No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.","text":["No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.","Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.(1).","J Eur Acad Dermatol Venereol","Carugno, A","Raponi, F","Locatelli, A G","Vezzoli, P","Gambini, D M","Di Mercurio, M","Robustelli Test, E","Sena, P","32339362"],"abstract":["Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.(1)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Carugno, A","Raponi, F","Locatelli, A G","Vezzoli, P","Gambini, D M","Di Mercurio, M","Robustelli Test, E","Sena, P"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339362","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16552","keywords":["covid-19","dupilumab","atopic dermatitis"],"locations":["Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1665264685661814784,"score":8.574329,"similar":[{"pmid":32330323,"title":"Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.","text":["Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.","Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.","J Eur Acad Dermatol Venereol","Ferrucci, S","Romagnuolo, M","Angileri, L","Berti, E","Tavecchio, S","32330323"],"abstract":["Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients."],"journal":"J Eur Acad Dermatol Venereol","authors":["Ferrucci, S","Romagnuolo, M","Angileri, L","Berti, E","Tavecchio, S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330323","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16527","keywords":["covid-19","atopic dermatitis","dupilumab","interstitial pneumonia"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664996915011387392,"score":903.96423},{"pmid":32223003,"title":"European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis.","text":["European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis.","Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.(1,2) Severely affected patients are often treated with immune-modulating systemic drugs.(3,4) On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.","J Eur Acad Dermatol Venereol","Wollenberg, Andreas","Flohr, Carsten","Simon, Dagmar","Cork, Michael J","Thyssen, Jacob P","Bieber, Thomas","de Bruin-Weller, Marjolein S","Weidinger, Stephan","Deleuran, Mette","Taieb, Alain","Paul, Carle","Trzeciak, Magdalena","Werfel, Thomas","Seneschal, Julien","Barbarot, Sebastien","Darsow, Ulf","Torrelo, Antonio","Stalder, Jean-Francois","Svensson, Ake","Hijnen, Dirkjan","Gelmetti, Carlo","Szalai, Zsuzsanna","Gieler, Uwe","De Raeve, Linda","Kunz, Barbara","Spuls, Phyllis","von Kobyletzki, Laura B","Folster-Holst, Regina","Chernyshov, Pavel V","Cristen-Zaech, Stephanie","Heratizadeh, Annice","Ring, Johannes","Vestergaard, Christian","32223003"],"abstract":["Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.(1,2) Severely affected patients are often treated with immune-modulating systemic drugs.(3,4) On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here."],"journal":"J Eur Acad Dermatol Venereol","authors":["Wollenberg, Andreas","Flohr, Carsten","Simon, Dagmar","Cork, Michael J","Thyssen, Jacob P","Bieber, Thomas","de Bruin-Weller, Marjolein S","Weidinger, Stephan","Deleuran, Mette","Taieb, Alain","Paul, Carle","Trzeciak, Magdalena","Werfel, Thomas","Seneschal, Julien","Barbarot, Sebastien","Darsow, Ulf","Torrelo, Antonio","Stalder, Jean-Francois","Svensson, Ake","Hijnen, Dirkjan","Gelmetti, Carlo","Szalai, Zsuzsanna","Gieler, Uwe","De Raeve, Linda","Kunz, Barbara","Spuls, Phyllis","von Kobyletzki, Laura B","Folster-Holst, Regina","Chernyshov, Pavel V","Cristen-Zaech, Stephanie","Heratizadeh, Annice","Ring, Johannes","Vestergaard, Christian"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32223003","week":"202014|Mar 30 - Apr 05","doi":"10.1111/jdv.16411","keywords":["COVID-19","SARS-CoV-2","atopic dermatitis","immunosuppressant","systemic therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135212859394,"score":396.55887},{"pmid":32320091,"title":"Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice.","text":["Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice.","Since the first case of \"pneumonia of unknown aetiology\" was diagnosed at the Wuhan Jinyintan Hospital in China on 30 December 2019, what was recognised thereafter as \"severe acute respiratory syndrome coronavirus 2\" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID- 19) and satisfying the epidemiological criteria for a label of \"pandemic.\" The ongoing SARS-CoV-2 pandemic is having a huge impact on dermatological practice including the marked reduction of face-to-face consultations in favour of teledermatology, the uncertainties concerning the outcome of COVID-19 infection in patients with common inflammatory disorders such as psoriasis or atopic dermatitis receiving immunosuppressive/immunomodulating systemic therapies; the direct involvement of dermatologists in COVID-19 care for patients assistance and new research needs to be addressed. It is not known yet, if skin lesions and derangement of the skin barrier could make it easier for SARS-CoV-2 to transmit via indirect contact; it remains to be defined if specific mucosal or skin lesions are associated with SARS-CoV-2 infection, although some unpublished observations indicate the occurrence of a transient varicelliform exanthema during the early phase of the infection. SARS-CoV-2 is a new pathogen for humans that is highly contagious, can spread quickly, and is capable of causing enormous health, economic and societal impacts in any setting. The consequences may continue long after the pandemic resolves, and new management modalities for dermatology may originate from the COVID-19 disaster. Learning from experience may help to cope with future major societal changes.","J Eur Acad Dermatol Venereol","Gisondi, P","Piaserico, S","Conti, A","Naldi, L","32320091"],"abstract":["Since the first case of \"pneumonia of unknown aetiology\" was diagnosed at the Wuhan Jinyintan Hospital in China on 30 December 2019, what was recognised thereafter as \"severe acute respiratory syndrome coronavirus 2\" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID- 19) and satisfying the epidemiological criteria for a label of \"pandemic.\" The ongoing SARS-CoV-2 pandemic is having a huge impact on dermatological practice including the marked reduction of face-to-face consultations in favour of teledermatology, the uncertainties concerning the outcome of COVID-19 infection in patients with common inflammatory disorders such as psoriasis or atopic dermatitis receiving immunosuppressive/immunomodulating systemic therapies; the direct involvement of dermatologists in COVID-19 care for patients assistance and new research needs to be addressed. It is not known yet, if skin lesions and derangement of the skin barrier could make it easier for SARS-CoV-2 to transmit via indirect contact; it remains to be defined if specific mucosal or skin lesions are associated with SARS-CoV-2 infection, although some unpublished observations indicate the occurrence of a transient varicelliform exanthema during the early phase of the infection. SARS-CoV-2 is a new pathogen for humans that is highly contagious, can spread quickly, and is capable of causing enormous health, economic and societal impacts in any setting. The consequences may continue long after the pandemic resolves, and new management modalities for dermatology may originate from the COVID-19 disaster. Learning from experience may help to cope with future major societal changes."],"journal":"J Eur Acad Dermatol Venereol","authors":["Gisondi, P","Piaserico, S","Conti, A","Naldi, L"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320091","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16515","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664815087646408705,"score":179.34158},{"pmid":32170800,"title":"Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.","text":["Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.","Health professions preventing and controlling Coronavirus Disease 2019 are prone to skin and mucous membrane injury, which may cause acute and chronic dermatitis, secondary infection and aggravation of underlying skin diseases. This is a consensus of Chinese experts on protective measures and advice on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related protection, eye protection, nasal and oral mucosa protection, outer ear, and hair protection. It is necessary to strictly follow standards of wearing protective equipment and specification of sterilizing and cleaning. Insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier. At the same time, using moisturizing products is highly recommended to achieve better protection.","Dermatol Ther","Yan, Yicen","Chen, Hui","Chen, Liuqing","Cheng, Bo","Diao, Ping","Dong, Liyun","Gao, Xinghua","Gu, Heng","He, Li","Ji, Chao","Jin, Hongzhong","Lai, Wei","Lei, Tiechi","Li, Li","Li, Liuyi","Li, Ruoyu","Liu, Dongxian","Liu, Wei","Lu, Qianjin","Shi, Ying","Song, Jiquan","Tao, Juan","Wang, Baoxi","Wang, Gang","Wu, Yan","Xiang, Leihong","Xie, Jun","Xu, Jinhua","Yao, Zhirong","Zhang, Furen","Zhang, Jianzhong","Zhong, Shaomin","Li, Hengjin","Li, Hang","32170800"],"abstract":["Health professions preventing and controlling Coronavirus Disease 2019 are prone to skin and mucous membrane injury, which may cause acute and chronic dermatitis, secondary infection and aggravation of underlying skin diseases. This is a consensus of Chinese experts on protective measures and advice on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related protection, eye protection, nasal and oral mucosa protection, outer ear, and hair protection. It is necessary to strictly follow standards of wearing protective equipment and specification of sterilizing and cleaning. Insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier. At the same time, using moisturizing products is highly recommended to achieve better protection."],"journal":"Dermatol Ther","authors":["Yan, Yicen","Chen, Hui","Chen, Liuqing","Cheng, Bo","Diao, Ping","Dong, Liyun","Gao, Xinghua","Gu, Heng","He, Li","Ji, Chao","Jin, Hongzhong","Lai, Wei","Lei, Tiechi","Li, Li","Li, Liuyi","Li, Ruoyu","Liu, Dongxian","Liu, Wei","Lu, Qianjin","Shi, Ying","Song, Jiquan","Tao, Juan","Wang, Baoxi","Wang, Gang","Wu, Yan","Xiang, Leihong","Xie, Jun","Xu, Jinhua","Yao, Zhirong","Zhang, Furen","Zhang, Jianzhong","Zhong, Shaomin","Li, Hengjin","Li, Hang"],"date":"2020-03-15T11:00:00Z","year":2020,"_id":"32170800","week":"202011|Mar 09 - Mar 15","doi":"10.1111/dth.13310","keywords":["covid-19","sars-cov-2","healthcare workers","protect","skin and mucous membrane barrier"],"source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640874708992000,"score":157.57802},{"pmid":32092539,"pmcid":"PMC7102551","title":"Is COVID-19 receiving ADE from other coronaviruses?","text":["Is COVID-19 receiving ADE from other coronaviruses?","One of the most perplexing questions regarding the current COVID-19 coronavirus epidemic is the discrepancy between the severity of cases observed in the Hubei province of China and those occurring elsewhere in the world. One possible answer is antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses. ADE modulates the immune response and can elicit sustained inflammation, lymphopenia, and/or cytokine storm, one or all of which have been documented in severe cases and deaths. ADE also requires prior exposure to similar antigenic epitopes, presumably circulating in local viruses, making it a possible explanation for the observed geographic limitation of severe cases and deaths.","Microbes Infect","Tetro, Jason A","32092539"],"abstract":["One of the most perplexing questions regarding the current COVID-19 coronavirus epidemic is the discrepancy between the severity of cases observed in the Hubei province of China and those occurring elsewhere in the world. One possible answer is antibody dependent enhancement (ADE) of SARS-CoV-2 due to prior exposure to other coronaviruses. ADE modulates the immune response and can elicit sustained inflammation, lymphopenia, and/or cytokine storm, one or all of which have been documented in severe cases and deaths. ADE also requires prior exposure to similar antigenic epitopes, presumably circulating in local viruses, making it a possible explanation for the observed geographic limitation of severe cases and deaths."],"journal":"Microbes Infect","authors":["Tetro, Jason A"],"date":"2020-02-25T11:00:00Z","year":2020,"_id":"32092539","week":"20209|Feb 24 - Mar 01","doi":"10.1016/j.micinf.2020.02.006","keywords":["antibody dependent enhancement","covid-19","coronavirus"],"source":"PubMed","topics":["Mechanism"],"weight":1,"locations":["Hubei","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664640875179802624,"score":147.03604}]}